Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisSTU:61R +2.07%67 PS Ratio is 0.34 as of Jul. 19, 2026, which is 13% above its 10-year median of 0.30. GuruFocus rates STU:61R with a GF Score™ of 67/100 and a GF Value™ of €4.39 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 117 Medical Distribution companies, Labo Euromedis ranks better than 57.26% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Labo Euromedis's share price is €4.94.
Labo Euromedis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €14.33. Hence, Labo Euromedis's PS Ratio for today is 0.34.
Warning Sign:
Labo Euromedis stock PS Ratio (=0.36) is close to 1-year high of 0.37.
The historical rank and industry rank for Labo Euromedis's PS Ratio or its related term are showing as below:
STU:61R'
s PS Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.3 Max: 0.74
Current: 0.36
During the past 13 years, Labo Euromedis's highest PS Ratio was 0.74. The lowest was 0.13. And the median was 0.30.
STU:61R's PS Ratio is ranked better than 57.26% of 117
companies
in the Medical Distribution industry
Industry Median: 0.4
vs STU:61R: 0.36
Labo Euromedis revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Labo Euromedis was 12.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -23.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -7.00% per year.
During the past 13 years, Labo Euromedis's highest 3-Year average Revenue per Share Growth Rate was 30.20% per year. The lowest was -39.50% per year. And the median was -0.10% per year.
Back to Basics: PS Ratio
Labo Euromedis (STU:61R) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Labo Euromedis PS Ratio Related Terms
Labo Euromedis PS Ratio Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's PS Ratio distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Labo Euromedis's Share Price of today is €4.94.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labo Euromedis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €14.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Labo Euromedis (STU:61R) has a PS Ratio of 0.34 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Labo Euromedis and its competitors. This is 13% above median its historical median of 0.30. Over the past decade, Labo Euromedis' PS Ratio has ranged from 0.13 to 0.74. According to the industry distribution chart, Labo Euromedis ranks #50 out of 117 companies in the Medical Distribution industry, placing it in the top 42.7%.
Is Labo Euromedis' PS Ratio too high?
Labo Euromedis' current PS Ratio of 0.34 is 13% above median its 10-year median of 0.30. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.74. The Medical Distribution industry median PS Ratio is 0.40. Labo Euromedis' value of 0.34 is 15% below this industry median. Based on the distribution chart, Labo Euromedis ranks #50 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Labo Euromedis has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' PS Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #50 out of 117 companies for PS Ratio. This puts Labo Euromedis in the upper half of its industry. The industry median PS Ratio is 0.40. Labo Euromedis' value of 0.34 is 15% below this benchmark. Historically, Labo Euromedis' own PS Ratio has ranged from 0.13 to 0.74 over the past decade. While the company's 10-year median is 0.30 vs. the industry median of 0.40, Labo Euromedis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.40, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current PS Ratio of 0.34 is 15% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current PS Ratio is 0.34, which is 13% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (STU:61R) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.39, compared to a current price of €4.94 — trading 12.5% above its estimated fair value. The current PS Ratio is 0.34, which is 13% above median its 10-year median of 0.30 and 15% below the Medical Distribution industry median of 0.40. Labo Euromedis' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Labo Euromedis (STU:61R), the current PS Ratio is 0.34 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (STU:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.94 is trading 12.5% above its estimated GF Value™ of €4.39.
GuruFocus considers Labo Euromedis to be Modestly Overvalued.
Key valuation signals for STU:61R:
PS Ratio: 0.34 (13% above median its 10-year median of 0.30)
GF Value™: €4.39 vs. price of €4.94 (12.5% above fair value)
Industry Position: 15% below the Medical Distribution median (#50 of 117)
No single metric tells the full story. See the STU:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
67GF Score
Get the complete analysis for STU:61R
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61R has been successfully added to your 
